口腔粉症:一个更新.
F-S Pontes1, G-B Ferreira, F-P Fonseca
1Department of Oral Pathology João de Barros Barreto University Hospital Mundurucus Street, nº 4487, Zip Code 66073-000, Guamá Belém, Pará, Brazil harp@ufpa.br.
Medicina oral, patologia oral y cirugia bucal
|June 18, 2023
概括
粉样性粉症是一种异常蛋白质沉积的疾病,最常影响口腔中的舌头. 系统性氨基粉症,特别是多发性骨髓瘤,表明预后较差.
科学领域:
- 口腔病理学 口腔病理学
- 系统性疾病 系统性疾病
- 蛋白质病变是一种蛋白质病变.
背景情况:
- 氨基粉症涉及任何器官的逐渐异常蛋白质沉积.
- 口腔粉症经常影响舌头,导致巨.
- 诊断需要活检,必须调查系统性参与.
结论:
- 系统性粉样性粉症,特别是当与多发性骨髓瘤相关时,呈现出最糟糕的预后.
- 了解临床病理特征有助于治疗和预后.
- 需要对口腔氨基粉症进行进一步的研究.
相关概念视频
Amyloid Fibrils
5.5K
5.5K
Alzheimer's Disease: Overview
532
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
Alzheimer's Disease: Treatment
223
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223
Atherosclerosis III: Management
15
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
15


